研究室の業績
2023年度 研究業績
Quantification of Melatonin, Caffeine, and Paraxanthine in Human Plasma Using Liquid Chromatography-Tandem Mass Spectrometry.
Yokokawa A, Takano H, Shimazaki H, Ogawa S, Fukae M, Akiyama H, Igarashi S, Furihata T, Shibasaki H.
Chromatographia 2024, in press. https://doi.org/10.1007/s10337-023-04308-6
Quantification of fluticasone propionate in human plasma by LC-MS/MS and its application in the pharmacokinetic study of nasal spray at clinical doses.
Yamagata A, Adachi R, Yokokawa A, Furihata T, Shibasaki H.
Drug Metab Pharmacokinet. 2023;54:100541.
Plasma 6β-hydroxycortisol to cortisol ratio as a less invasive cytochrome P450 3A phenotyping method.
Hirano R, Yokokawa A, Furihata T, Shibasaki H.
Br J Clin Pharmacol. 2023, in press.
FTY720 requires vitamin B12-TCN2-CD320 signaling in astrocytes to reduce disease in an animal model of multiple sclerosis.
Jonnalagadda D, Kihara Y, Groves A, Ray M, Saha A, Ellington C, Lee-Okada HC, Furihata T, Yokomizo T, Quadros EV, Rivera R, Chun J.
Cell Rep. 2023;42(12):113545.
Rapid Quantification of Microvessels of Three-Dimensional Blood–Brain Barrier Model Using Optical Coherence Tomography and Deep Learning Algorithm.
Zhang H, Kang D, Piantino M, Tominaga D, Fujimura T, Nakatani N, Taylor NJ, Furihata T, Matsusaki M, Fujita S.
Biosensors 2023, 13(8), 818.
Transferrin receptor-targeting property of pabinafusp alfa facilitates its uptake by various types of human brain-derived cells in vitro.
Fukatsu T*, Morio H*, Furihata T, Sonoda H.
Front Drug Deliv. 2023,3;2023.1082672.
*, equally contributed.
Control of blood capillary networks and holes in blood-brain barrier models by regulating elastic modulus of scaffolds.
Shang Y, Piantino M, Zeng J, Louis F, Xie Z, Furihata T, Matsusaki M.
Mater Today Bio. 2023,21;100714
Increased PDGFRB and NF-κB signaling caused by highly prevalent somatic mutations in intracranial aneurysms.
Shima Y, Sasagawa S, Ota N, Oyama R, Tanaka M, Kubota-Sakashita M, Kawakami H, Kobayashi M, Takubo N, Ozeki AN, Sun X, Kim YJ, Kamatani Y, Matsuda K, Maejima K, Fujita M, Noda K, Kamiyama H, Tanikawa R, Nagane M, Shibahara J, Tanaka T, Rikitake Y, Mataga N, Takahashi S, Kosaki K, Okano H, Furihata T, Nakaki R, Akimitsu N, Wada Y, Ohtsuka T, Kurihara H, Kamiguchi H, Okabe S, Nakafuku M, Kato T, Nakagawa H, Saito N, Nakatomi H.
Sci Transl Med. 2023;15(700):eabq7721.
Quaternization of high molecular weight chitosan for increasing intestinal drug absorption using Caco-2 cells as an in vitro intestinal model.
Wongwanakul R, Aueviriyavit S, Furihata T, Gonil P, Sajomsang W, Maniratanachote R, Jianmongkol S.
Sci Rep. 2023;13(1):7904.
Calculation of Human Melatonin Partial Metabolic Clearance in Healthy Adult Volunteers for Investigation of a Novel in Vivo CYP1A2 Phenotyping Method: A Pilot Study.
Ohki S, Ogawa S, Takano H, Shimazaki H, Fukae M, Furihata T, Shibasaki H, Yokokawa A.
Biol Pharm Bull. 2023;46(5):736-740.
Comparative study of stable isotope-labeled internal standard substances for the LC-MS/MS determination of the urinary excretion of melatonin.
Shimazaki H, Ogawa S, Takano H, Ohki S, Fukae M, Furihata T, Shibasaki H, Yokokawa A.
Med Mass Spectr. 2023;7(1): DOI: 10.24508/mms.2023.06.004.
2022年度 研究室の業績
Rapid and Stable Formation Method of Human Astrocyte Spheroid in a High Viscous Methylcellulose Medium and Its Functional Advantages.
Bioengineering. 2023;10(3):349.
Usefulness of a humanized tricellular static transwell blood-brain barrier model as a microphysiological system for drug development applications. - A case study based on the benchmark evaluations of blood-brain barrier microphysiological system.
Regen Ther. 2023, 22:192-202.
siRNA delivery to lymphatic endothelial cells via ApoE-mediated uptake by lipid nanoparticles.
J Control Release. 2022, 353:125-133.
Influence of Anticoagulants and Storage Conditions During Blood Sample Collection on Determination of the 6β-hydroxycortisol/cortisol Ratio by LC-MS/MS.
Shibasaki H, Yokokawa A, Furihata T.
BUNSEKI KAGAKU. 2022, 71(6):357-363.
The impaired distribution of adenosine deaminase isoenzymes in multiple sclerosis plasma and cerebrospinal fluid.
Kutryb-Zajac B, Kawecka A, Caratis F, Urbanowicz K, Braczko A, Furihata T, Karaszewski B, Smolenski RT, Rutkowska OA.
Front. Mol. Neurosci., 2022,15:998023.
Generation of a Human Conditionally Immortalized Cell-based Multicellular Spheroidal Blood-Brain Barrier Model for Permeability Evaluation of Macromolecules.
Bio Protoc. 2022; 12(15):e4465.
Human Immortalized Cell-Based Blood-Brain Barrier Spheroid Models Offer an Evaluation Tool for the Brain Penetration Properties of Macromolecules.
Mol Pharm. 2022; 19(8):2754-2764.
cGAS and DDX41-STING mediated intrinsic immunity spreads intercellularly to promote neuroinflammation in SOD1 ALS model.
iScience. 2022;25(6):104404.
Development of a three-dimensional blood-brain barrier network with opening capillary structures for drug transport screening assays.
Mater Today Bio. 2022; 15: 100324.
Effects of 11β-hydroxysteroid dehydrogenase 2 activity on the prediction accuracy of plasma unbound cortisol concentration based on salivary cortisol.
Yokokawa A, Kitano A, Tanaka D, Higashi K, Yanada S, Shimizu K, Furihata T, Shibasaki H.
Med Mass Spectr, 2022; 6(1): 45-51.
Development and Validation of an LC-MS/MS-Based Method for Quantifying Urinary Endogenous 6-Hydroxymelatonin.
Ohki S, Kunimatsu M, Ogawa S, Takano H, Furihata T, Shibasaki H, Yokokawa A.
Chem Pharm Bull. 2022; 70(5): 375-382.
In Vitro-In Vivo Correlation of Blood-Brain Barrier Permeability of Drugs: A Feasibility Study Towards Development of Prediction Methods for Brain Drug Concentration in Humans.
Ito R, Morio H, Baba T, Sakaguchi Y, Wakayama N, Isogai R, Yamaura Y, Komori T, Furihata T.
Pharm Res. 2022, 39(7):1575-1586.
2021年度 研究室の業績
Functional analysis of human brain endothelium using a microfluidic device integrating a cell culture insert
Miura S, Morimoto Y, Furihata T, Takeuchi S.
APL Bioengineering. 2022, 6, 016103.
Astrocyte Control of Zika Infection Is Independent of Interferon Type I and Type III Expression.
Biology (Basel). 2022;11(1):143.
Evaluating a Targeted Cancer Therapy Approach Mediated by RNA trans-Splicing In Vitro and in a Xenograft Model for Epidermolysis Bullosa-Associated Skin Cancer.
Woess K, Sun Y, Morio H, Stierschneider A, Kaufmann A, Hainzl S, Trattner L, Kocher T, Tockner B, Leb-Reichl V, Steiner M, Brachtl G, South AP, Bauer JW, Reichelt J, Furihata T, Wally V, Koller U, Piñón Hofbauer J, Guttmann-Gruber C.
Int J Mol Sci. 2022;23(1):575.
Dried blood spots analysis of 6β-hydroxycortisol and cortisol using liquid chromatography/tandem mass spectrometry for calculating 6β-hydroxycortisol to cortisol ratio.
J Mass Spectrom. 2021;56(12):e4790.
Haploinsufficiency of microglial MyD88 ameliorates Alzheimer's pathology and vascular disorders in APP/PS1-transgenic mice.
Quan W, Luo Q, Hao W, Tomic I, Furihata T, Schulz-Schäffer W, Menger MD, Fassbender K, Liu Y.
Glia. 2021, 69(8):1987-2005.
Development, characterization and potential applications of a multicellular spheroidal human blood-brain barrier model integrating three conditionally immortalized cell lines.
Kitamura K, Umehara K, Ito R, Yamaura Y, Komori T, Morio H, Akita H, Furihata T.
Biol Pharm Bull. 2021, 44(7):984-991.
Selected as a Featured article in this journal!
Effects of islatravir (4'-ethynyl-2-fluoro-2'-deoxyadenosine or EFdA) on renal tubular cells and islatravir's interactions with organic anion transporters.
Kaneko M, Reien Y, Morio H, Fukuuchi T, Kaneko K, Hirayama Y, Hashimoto H, Kuwata N, Mitsuya H, Anzai N.
J Pharmacol Sci. 2021;146(2):82-87.
Conserved lysine residues in decorin binding proteins of Borrelia garinii are critical in adhesion to human brain microvascular endothelial cells.
Pietikäinen A, Åstrand M, Cuellar J, Glader O, Elovaara H, Rouhiainen M, Salo J, Furihata T, Salminen TA, Hytönen J.
Mol Microbiol. 2021, 115(6):1395-1409.
2020年度研究室の業績
Effect of UGT1A1, CYP3A and CES Activities on the Pharmacokinetics of Irinotecan and its Metabolites in Patients with UGT1A1 Gene Polymorphisms.
Eur J Drug Metab Pharmacokinet. 2021, 46(2):317-324..
Ischemic stroke disrupts the endothelial glycocalyx through activation of proHPSE via acrolein exposure.
J Biol Chem. 2020 Oct 30:jbc.RA120.015105. doi: 10.1074/jbc.RA120.015105.
http://www.qlifepro.com/news
https://www.eurekalert.org/pub_releases/2021-02/tuos-sol022221.php
Identification of AR-V7 downstream genes commonly targeted by AR/AR-V7 and specifically targeted by AR-V7 in castration resistant prostate cancer.
Transl Oncol. 2020;14(1):100915.
Interstitial flow regulates in vitro three-dimensional self-organized brain micro-vessels.
Biochem Biophys Res Commun. 2020, in press.
NLRP3 Is Involved in the Maintenance of Cerebral Pericytes.
Quan W, Luo Q, Tang Q, Furihata T, Li D, Fassbender K, Liu Y.
Front. Cell. Neurosci. 2020;14:276. doi: 10.3389/fncel.2020.00276. eCollection 2020.
In vitro self-organized three-dimensional model of the blood-brain barrier microvasculature.
Biomed Mater. 2020, in press.
JPH203, a newly developed anti-cancer drug, shows a preincubation inhibitory effect on L-type amino acid transporter 1 function.
Okunushi K, Furihata T, Morio H, Muto Y, Higuchi K, Kaneko M, Otsuka Y, Ohno Y, Watanabe Y, Reien Y, Nakagawa K, Sakamoto S, Wakashin H, Shimojo N, Anzai N.
J Pharmacol Sci. 2020;144(1):16-22.
Midazolam Intoxication in a Premature Neonate.
Endo M, Hirano R, Shibasaki H, Yokokawa A, Furuta T, Abe K, Morita K, Tanaka S, Hirano T, Sakurai M, Mizuno K.
Clin Ther. 2020;42(5):946-951.
2019年度研究室の業績
原著
Expression of L-type amino acid transporter 1 as a molecular target for prognostic and therapeutic indicators in bladder carcinoma.
Maimaiti M, Sakamoto S, Yamada Y, Sugiura M, Rii J, Takeuchi N, Imamura Y, Furihata T, Ando K, Higuchi K, Xu M, Sazuka T, Nakamura K, Kaneda A, Kanai Y, Kyprianou N, Ikehara Y, Anzai N, Ichikawa T.
Sci Rep. 2020 Jan 28;10(1):1292. doi: 10.1038/s41598-020-58136-x.
Characterization of the expression of LAT1 as a prognostic indicator and a therapeutic target in renal cell carcinoma.
Higuchi K, Sakamoto S, Ando K, Maimaiti M, Takeshita N, Okunushi K, Reien Y, Imamura Y, Sazuka T, Nakamura K, Matsushima J, Furihata T, Ikehara Y, Ichikawa T, Anzai N.
Sci Rep. 2019;9(1):16776. doi: 10.1038/s41598-019-53397-7.
A Human Immortalized Cell-Based Blood-Brain Barrier Triculture Model: Development and Characterization as a Promising Tool for Drug-Brain Permeability Studies.
Ito R, Umehara K, Suzuki S, Kitamura K, Nunoya KI, Yamaura Y, Imawaka H, Izumi S, Wakayama N, Komori T, Anzai N, Akita H, Furihata T.
Mol Pharm. 2019 Oct 15. doi: 10.1021/acs.molpharmaceut.9b00519. [Epub ahead of print]
The protocol can be found here.
Indirect activation of constitutive androstane receptor in three-dimensionally cultured HepG2 cells.
Yokobori K, Azuma I, Chiba K, Akita H, Furihata T, Kobayashi K.
Biochem Pharmacol. 2019;168:26-37.
Sodium-coupled monocarboxylate transporter 1 interacts with the RING finger- and PDZ domain-containing protein PDZRN3.
Otsuka Y, Furihata T, Nakagawa K, Ohno Y, Reien Y, Ouchi M, Wakashin H, Tsuruoka S, Anzai N.
J Physiol Sci. 2019, in press.
Large-Scale Quantitative Comparison of Plasma Transmembrane Proteins between Two Human Blood-Brain Barrier Model Cell Lines, hCMEC/D3 and HBMEC/ciβ.
Masuda T, Hoshiyama T, Uemura T, Hirayama-Kurogi M, Ogata S, Furukawa A, Couraud PO, Furihata T, Ito S, Ohtsuki S.
Mol Pharmaceut. 2019;16(5):2162-2171.
Identification of equol-7-glucuronide-4'-sulfate, monoglucuronides and monosulfates in human plasma of 2 equol producers after administration of kinako by LC-ESI-MS.
Obara A, Kinoshita M, Hosoda K, Yokokawa A, Shibasaki H, Ishii K.
Pharmacol Res Perspect. 2019;7(3):e00478.
2018年度研究室の業績
原著・総説および著書
（降幡分は千葉大学在籍時のものです）
原著
Sensitive and Simultaneous Quantitation of 6β-Hydroxycortisol and Cortisol in Human Plasma by LC-MS/MS Coupled with Stable Isotope Dilution Method
Ryohei Hirano, Akitomo Yokokawa, Takashi Furuta, Hiromi Shibasaki
J Mass Spectrom, 53, 665-674 (2018)
Different Response Profiles of Gastrointestinal Cancer Cells to an L-Type Amino Acid Transporter Inhibitor, JPH203.
Muto Y, Furihata T, Kaneko M, Higuchi K, Okunushi K, Morio H, Reien Y, Uesato M, Matsubara H, Anzai N.
Anticancer Res. 2019;39(1):159-165.
Polyamines stimulate the CHSY1 synthesis through the unfolding of the RNA G-quadruplex at the 5'-untraslated region.
Yamaguchi K, Asakura K, Imamura M, Kawai G, Sakamoto T, Furihata T, Linhardt RJ, Igarashi K, Toida T, Higashi K.
Biochem J. 2018;475(23):3797-3812.
Synthesis of novel benzbromarone derivatives designed to avoid metabolic activation.
Ohe T, Umezawa R, Kitagawara Y, Yasuda D, Takahashi K, Nakamura S, Abe A, Sekine S, Ito K, Okunushi K, Morio H, Furihata T, Anzai N, Mashino T.
Bioorg Med Chem Lett. 2018;28(23-24):3708-3711.
Differentiated HASTR/ci35 cells: A promising in vitro human astrocyte model for facilitating CNS drug development studies.
Kitamura K, Ito R, Umehara K, Morio H, Saito K, Suzuki S, Hashimoto M, Saito Y, Anzai N, Akita H, Chiba K, Furihata T.
J Pharmacol Sci. 2018;137(4):350-358.
Cancer-type organic anion transporting polypeptide 1B3 is a target for cancer suicide gene therapy using RNA trans-splicing technology.
Sun Y, Piñón Hofbauer J, Harada M, Wöss K, Koller U, Morio H, Stierschneider A, Kitamura K, Hashimoto M, Chiba K, Akita H, Anzai N, Reichelt J, Bauer JW, Guttmann-Gruber C, Furihata T.
Cancer Lett. 2018;433:107-116.
Development of a Caco-2 Cell Line Carrying the Human Intestine-Type CES Expression Profile as a Promising Tool for Ester-Containing Drug Permeability Studies.
Ishizaki Y, Furihata T, Oyama Y, Ohura K, Imai T, Hosokawa M, Akita H, Chiba K.
Biol Pharm Bull. 2018;41(5):697-706.
In Vivo Introduction of mRNA Encapsulated in Lipid Nanoparticles to Brain Neuronal Cells and Astrocytes via Intracerebroventricular Administration.
Tanaka H, Nakatani T, Furihata T, Tange K, Nakai Y, Yoshioka H, Harashima H, Akita H.
Mol Pharmaceutics. 2018;15(5):2060-2067.
2017年度研究室の業績
原著
（降幡分は千葉大学時代のものです）
Cancer-Type OATP1B3 mRNA in Extracellular Vesicles as a Promising Candidate for a Serum-Based Colorectal Cancer Biomarker.
Morio H, Sun Y, Harada M, Ide H, Shimozato O, Zhou X, Higashi K, Yuki R, Yamaguchi N, Hofbauer JP, Guttmann-Gruber C, Anzai N, Akita H, Chiba K, Furihata T.
Biol Pharm Bull. 2018;41(3):445-449.
Development of a New Conditionally Immortalized Human Liver Sinusoidal Endothelial Cells.
Zhu M, Koibuchi A, Ide H, Morio H, Shibuya M, Kamiichi A, Tsubota A, Anzai N, Akita H, Chiba K, Furihata T.
Biol Pharm Bull. 2018;41(3):440-444.
Soluble CD40 ligand disrupts the blood-brain barrier and exacerbates inflammation in experimental autoimmune encephalomyelitis.
Masuda H, Mori M, Umehara K, Furihata T, Uchida T, Uzawa A, Kuwabara S.
J Neuroimmunol. 2018 Mar 15;316:117-120.
Extracellular Vesicles as Biomarkers for the Detection of a Tumor Marker Gene in Epidermolysis Bullosa-Associated Squamous Cell Carcinoma.
Sun Y, Woess K, Kienzl M, Leb-Reichl VM, Feinle A, Wimmer M, Zauner R, Wally V, Luetz-Meindl U, Mellerio JE, Fuentes I, South AP, Bauer JW, Reichelt J, Furihata T, Guttmann-Gruber C, Piñón Hofbauer J.
J Invest Dermatol. 2018 May;138(5):1197-1200.
Characterization of an L-Carnitine Transport System in Murine Photoreceptor Cell Line.
Ohno Y, Otsuka Y, Nohara M, Furihata T, Kuse Y, Itoh Y, Hara H, Anzai N.
Biol Pharm Bull. 2017;40(12):2110-2116.
A New Conditionally Immortalized Human Fetal Brain Pericyte Cell Line: Establishment and Functional Characterization as a Promising Tool for Human Brain Pericyte Studies.
Umehara K, Sun Y, Hiura S, Hamada K, Itoh M, Kitamura K, Oshima M, Iwama A, Saito K, Anzai N, Chiba K, Akita H, Furihata T.
Mol Neurobiol. 2018 Jul;55(7):5993-6006.
Cancer-type OATP1B3 mRNA has the potential to become a detection and prognostic biomarker for human colorectal cancer.
Sun Y, Harada M, Shimozato O, Souda H, Takiguchi N, Nabeya Y, Kamijo T, Akita H, Anzai N, Chiba K, Furihata T.
Biomark Med. 2017 Aug;11(8):629-639.
総説
Functional Expression of Organic Ion Transporters in Astrocytes and Their Potential as a Drug Target in the Treatment of Central Nervous System Diseases.
Furihata T, Anzai N.
Biol Pharm Bull. 2017;40(8):1153-1160.
2016年度研究室の業績
原著・総説および著書
（降幡分は千葉大学在籍時のものです）
Human organic anion transporter 2 is an entecavir, but not tenofovir, transporter.
Furihata T, Morio H, Zhu M, Suzuki Y, Ide H, Tsubota A, Fu Z, Anzai N, Chiba K.
Drug Metab Pharmacokinet. 2017 Feb;32(1):116-119.
Polyamines release the let-7b-mediated suppression of initiation codon recognition during the protein synthesis of EXT2.
Imamura M, Higashi K, Yamaguchi K, Asakura K, Furihata T, Terui Y, Satake T, Maegawa J, Yasumura K, Ibuki A, Akase T, Nishimura K, Kashiwagi K, Linhardt RJ, Igarashi K, Toida T.
Sci Rep. 2016 Sep 21;6:33549.
Involvement of ESE-3, epithelial-specific ETS factor family member 3, in transactivation of the ABCB1 gene via pregnane X receptor in intestine-derived LS180 cells but not in liver-derived HepG2 cells.
Kameyama N, Kobayashi K, Shimizu S, Yamasaki Y, Endo M, Hashimoto M, Furihata T, Chiba K.
Drug Metab Pharmacokinet. 2016 Oct;31(5):340-348.
著書
古田 隆，柴崎 浩美，横川 彰朋
テーラーメイド医療―薬物治療の個別化― 第2版．京都廣川書店出版，2017年3月，385 pp.
2015年度研究室の業績
原著・総説
（降幡分は千葉大学時代のものです）
Characterization of release profile of ornithine carbamoyltransferase from primary rat hepatocytes treated with hepatotoxic drugs: Implications for its unique potential as a drug-induced liver injury biomarker.
Furihata T, Aizawa T, Koibuchi A, Zhu M, Yamasaki Y, Shibuya M, Chiba K.
Drug Metab Pharmacokinet. 2016 Feb;31(1):102-105.
Establishment and characterization of a new conditionally immortalized human astrocyte cell line.
Furihata T, Ito R, Kamiichi A, Saito K, Chiba K.
J Neurochem. 2016 Jan;136(1):92-105.
Influencing factors on serum 25-hydroxyvitamin D3 levels in Japanese chronic hepatitis C patients.
Atsukawa M, Tsubota A, Shimada N, Yoshizawa K, Abe H, Asano T, Ohkubo Y, Araki M, Ikegami T, Kondo C, Itokawa N, Nakagawa A, Arai T, Matsushita Y, Nakatsuka K, Furihata T, Chuganji Y, Matsuzaki Y, Aizawa Y, Iwakiri K.
BMC Infect Dis. 2015 Aug 19;15:344.
Cancer-type Organic Anion Transporting Polypeptide 1B3: Current Knowledge of the Gene Structure, Expression Profile, Functional Implications and Future Perspectives.
Furihata T, Sun Y, Chiba K.
Curr Drug Metab. 2015;16(6):474-85.
Differential inhibition features of direct-acting anti-hepatitis C virus agents against human organic anion transporting polypeptide 2B1.
Furihata T, Fu Z, Suzuki Y, Matsumoto S, Morio H, Tsubota A, Matsumoto S, Chiba K.
Int J Antimicrob Agents. 2015 Oct;46(4):381-8.
Interferon-λ3 polymorphisms in pegylated-interferon-α plus ribavirin therapy for genotype-2 chronic hepatitis C.
Ishiguro H, Abe H, Seki N, Sugita T, Aida Y, Itagaki M, Sutoh S, Shimada N, Furihata T, Tsubota A, Aizawa Y.
World J Gastroenterol. 2015 Apr 7;21(13):3904-11.
特許申請
柴崎浩美，古田隆，横川彰朋，平野良平
ヒトにおけるCYP3A酵素活性の評価方法 (フェノタイプ検査法)
特願2015-119065 (2015)
学会発表
※時間の都合上、更新を一時停止しています。
国際学会
2019年度
17th International Congress of Therapeutic Drug Monitoring & Clinical Toxicology (IATDMCT)
2019年9月 於 Foz do Iguaçu, Brazil
Simultaneous measurement of regorafenib and its metabolites in human plasma using HPLC and pharmacokinetics in Japanese patients.
H. Shibasaki-Hirano, C. Usukura, S. Katsumata, Y. Hirahara, R. Hirano, A. Yokokawa, T. Maezono, K. Kawai, M. Nishioka, T. Kobayashi, N. Okano, F. Nagashima, and J. Furuse.
The 13th International Conference on Cerebral Vascular Biology
2019年6月 於 Miami, USA
Development of a human immortalized cell-based multicellular spheroidal blood-brain barrier model: A promising platform for evaluation of permeability of various drugs.
K. Umehara, S. Izumi, N. Wakayama, T. Komori, R. Ito, K. Nunoya, Y. Yamaura, H. Imawaka, N. Anzai, H. Akita, T. Furihata.
A novel human immortalized cell-based blood-brain barrier triple co-culture model for predicting brain permeability of CNS drug candidates.
K. Kitamura, K. Umehara, R. Ito, K. Nunoya, Y. Yamaura, H. Imawaka, S. Izumi, N. Wakayama, T. Komori, N. Anzai, H. Akita, T. Furihata.
2018年度
（2018以前の降幡分は千葉大学時代のものです）
16th International Congress of Therapeutic Drug Monitoring & Clinical Toxicology (IATDMCT)
2018年9月 於 Brisbane, Australia
H. Shibasaki-Hirano, A. Yamagata, M. Saito, R. Hirano, A. Yokokawa, A. Obara, K. Ishii, T. Furuta
Measurement of plasma fluticasone propionate after multiple nasal administration
A. Yokokawa, S. Yamamoto, R. Hirano, A. Obara, K. Ishii, T. Furuta, and H. Shibasaki-Hirano
Production of erlotinib and gefitinib metabolites via in vitro metabolism for HPLC-UV analysis
2017年度
15th International Congress of Therapeutic Drug Monitoring & Clinical Toxicology (IATDMCT)
2017年9月，Kyoto
H Shibasaki-Hirano, R Adachi, A Yamagata, R Hirano, A Yokokawa, K Hosoda, A Obara, K Ishii, T Furuta
A sensitive LC-MS/MS method for quantification of fluticasone propionatein human plasma after intranasal administration
A Yokokawa, S Kaneko, S Endo, R Hirano, F Nagashima, D Naruge, N Okano, T Kobayashi, K Kawai, J Furuse, H Shibasaki-Hirano, T Furuta
Pharmacokinetic analysis of irinotecan and its metabolite to evaluate UGT1A1 and CYP3A activities in patients with UGT1A1 gene polymorphism
R Hirano, H Shibasaki, A Yokokawa, T Furuta
In vivo phenotyping for CYP3A by a single-point determination of plasma concentration ratio of endogenous 6β-hydroxycortisol to cortisol
2015年度
14th International Congress of Therapeutic Drug Monitoring & Clinical Toxicology (IATDMCT)
2015年10月，Rotterdam
Hiromi Shibasaki-Hirano, Yuhei Ohomori, Noriyuki Fukawa, Akitomo Yokokawa, Fumio Nagashima, Akiyoshi Kasuga, Daisuke Naruge, Hiroshi Kitamura, Naohiro Okano, Junji Furuse, Takashi Furutad
Clinical pharmacokinetics of 3-weekly docetaxel in cancer patients
Akitomo Yokokawa, Risa Ono, Kaori Hosoda, Kazuo Ishii, Takashi Furuta, and Hiromi Shibasaki-Hirano Separation and quantitative determination of the BCR-Abl tyrosine kinase inhibitors in human plasma by high-performance liquid chromatography with ultraviolet detection
EB house Research Seminar
2015年７月 Saltzburg, Austria
Tomomi Furihata
Cancer-type Organic Anion Transporting Polypeptide 1B3：Current Knowledge of the Gene Structure, Expression Profile, Functional Implications, and Research Updates
国内学会・招待講演・セミナー
（2018以前の降幡分は千葉大学時代のものです）
2019年度
日本薬学会第140年会
2020年３月、京都
唾液を用いた血中コルチゾール非結合型濃度の予測に及ぼす11β-HSD2活性の影響
横川 彰朋，北野 彩，田中 大地，東 海，簗田 駿，清水 康平，平野 良平，古田 隆，降幡 知巳，柴崎 浩美
HPLC-UVによるタキサン系抗がん薬ドセタキセルの血中非結合型濃度の定量法の検討
江間 義大、大森 悠平、府川 哲之、小栗 卓朗、横川 彰朋、降幡 知巳、柴﨑 浩美
細胞アッセイ研究会2019年度シンポジウム
2020年1月、つくば
ヒト型血液脳関門・生体模倣システムの開発 ～血液脳関門機能パラメーターによる既存モデルと新規開発モデルの比較研究～
北村 貴美子、最上 由香里、干川 和枝、A. Figarol、松崎 典弥、降幡 知巳、石田 誠一、佐藤 薫
日本薬物動態学会 第３４回年会
2019年12月、つくば
中枢作用薬開発を促進する条件的不死化細胞と生体模倣によるヒト血液脳関門モデル
降幡知巳
第41回生体膜と薬物の相互作用シンポジウム
2019年10月、千葉
ヒト血液脳関門機能解析に有用な新規ヒト不死化細胞血液脳関門スフェロイドモデル
梅原 健太、和泉 沙希、若山 直美、小森 高文、伊藤 涼、布谷 憲一、山浦 由之、今若 治夫、秋田 英万、降幡 知巳 （優秀発表賞）
第４回トランスポーター研究会関東部会
2019年10月、東京
網羅的遺伝子発現解析によるヒトアストロサイトの分化形質および活性化に関わるトランスポーターの探索
北村 啓太、梅原 健太、森尾 花恵、安西 尚彦、秋田 英万、降幡 知巳 （優秀発表賞）
第36回 日本TDM学会・学術大会
2019年5月、東京
血中6β-hydroxycoritosl/cortisol濃度比を指標としたCYP3A活性の個人間変動および日内・日間変動
平野良平、古田隆、横川彰朋、柴崎浩美
第19回 遺伝子・デリバリー研究会
2019年5月、千葉
Development of ssPalm-based nanoparticles for suicide gene delivery into cancer cells.
Kakuta A, Furihata T, Tanaka K, Morio H, Hofbauer JP, Gruber C, Tange K, Nakai Y, Yoshioka H, Akita H.
2018年度
第139回日本薬学会
2019年3月、千葉
降幡知巳
薬物脳送達技術開発を加速するヒト不死化細胞三次元血液脳関門モデル
再生医療関連技術を活用した動物実験代替法検討会」第６回検討会
2018年12月、大阪
降幡知巳
中枢創薬においてヒト血液脳関門モデルに期待される役割とその開発状況
第二回中枢移行性評価技術検討会（東京）
2018年11月、東京
降幡知巳
In vitroヒト血液脳関門モデルの創薬実装を目指して：どう作り、どう使うか、私達の取り組みも踏まえて
日本食品化学学会 第24回総会・学術大会
2018年5月、東京
小原 映，木下 瑞貴，細田 香織，柴崎 浩美，横川 彰朋，石井 和夫
ヒト血漿中におけるEquolの主要代謝物の同定
2017年度
日本薬学会第138年会
2018年3月，金沢
木下 瑞貴, 小原 映, 細田 香織, 柴崎 浩美, 横川 彰朋, 石井 和夫
LC-MS/MS によるヒト血漿中 Equol およびその抱合 代謝物の分析法の開発と代謝物プロファイル
第61回日本薬学会関東支部会
2017年9月，東京
降幡知巳
中枢創薬への実装を目指したヒト不死化細胞血液脳関門モデル開発
日本食品化学学会第23回総会・学術大会
2017年6月，三重
木下 瑞貴, 小原 映, 細田 香織, 柴崎 浩美, 横川 彰朋, 石井 和夫
きな粉摂取後のヒト血漿中equolとその抱合代謝物の分析
2016年度
日本薬学会第137年会
2017年3月，仙台
木下瑞貴，小原映，細田香織，柴崎浩美，横川彰朋，石井和夫
LC-MS/MS によるequol とその鏡像異性体を含む抱合代謝物の分析の検討
小原映，木下瑞貴，細田香織，柴崎浩美，横川彰朋，石井和夫
月経周期延長に影響するイソフラボン抱合代謝物の分析
横浜市立大学生命環境コース 教室セミナー
2017年1月，横浜
降幡知巳
血液脳関門：その構造と機能、in vitro再構築に向けた取り組み
第38回生体膜と薬物の相互作用シンポジウム
2016年11月，名古屋
降幡知巳
分化型ヒト不死化アストロサイトを用いたアストログリアトランスポーターの同定とその治療標的としての展望
日本薬物動態学会第31回年会 (JSSX-KASP joint symposium)
2016年10月，松本
第41回日本医用マススペクトル学会年会
2016年9月，名古屋
平野良平，柴崎浩美，横川彰朋，古田 隆
LC-MS/MSによる血中6β-ヒドロキシコルチゾールとコルチゾールの超高感度定量法の開発
木下瑞貴，細田 香織，小原 映，柴﨑浩美，横川彰朋，石井和夫
LC-MS/MSによるヒト血漿中におけるequolとその抱合代謝物の分析法の検討
第33回日本TDM学会・学術大会
2016年5月，宇都宮
横川彰朋，細川真優美，平野良平，細田香織，石井和夫，柴崎浩美，古田 隆
血中4β-ヒドロキシコレステロール濃度はCYP3A活性のバイオマーカーとして有用か?
平野良平，横川彰朋，柴崎浩美，古田 隆
血中 6β-ヒドロキシコルチゾール/血中コルチゾール濃度比に基づく 新規ヒト in vivo CYP3A 活性評価法
2015年度
第30会日本薬物動態学会(JSSX-KASP joint symposium)
2015年11月，東京
Tomomi Furihata.
Development of an immortalized human cell-based in vitro blood-brain barrier model and its potential applications to central nervous system drug development
第40回日本医用マススペクトル学会年会
2015年9月，浜松
横川彰朋，八郷雅弘，平野良平，細田香織，石井和夫，古田 隆，柴崎浩美
LC-MS/MSによる尿中コルチゾール及びコルチゾンの6α- / 6β-水酸化代謝物の分離定量法
木下瑞貴，細田香織，柴崎浩美，横川彰朋，石井和夫
LC-MS/MS法による大豆イソフラボンおよびエクオールとその抱合代謝物の一斉分析法の検討
塩川亮太，細田香織，柴崎浩美，横川彰朋，石井和夫
LC-MS/MS法によるヒト尿中におけるバニリルマンデル酸，ホモバニリン酸，メタネフリン，ノルメタネフリンおよびクレアチニンの同時定量法の検討